Fusion inhibitors, T-20; chemokine variants; tat and interferon antibodies: Gallo describes three new treatment approaches.
James
J S
JS
D016915:AIDS Vaccines / Q000276:immunology; D000918:Antibody Specificity; D001665:Binding Sites; D015704:CD4 Antigens / Q000378:metabolism; D018925:Chemokines / Q000378:metabolism* / Q000627:therapeutic use; D015507:Drugs, Investigational; D015756:Genes, tat / Q000276:immunology / Q000502:physiology*; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology / Q000502:physiology*; D019707:Receptors, Chemokine / Q000378:metabolism*
D016915:AIDS Vaccines; D015704:CD4 Antigens; D018925:Chemokines; D015507:Drugs, Investigational; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D016898:Interferon-alpha; D019707:Receptors, Chemokine